JP5723768B2 - 髄膜炎菌性多価未変性外膜小胞ワクチン、その作製方法およびその使用 - Google Patents

髄膜炎菌性多価未変性外膜小胞ワクチン、その作製方法およびその使用 Download PDF

Info

Publication number
JP5723768B2
JP5723768B2 JP2011511892A JP2011511892A JP5723768B2 JP 5723768 B2 JP5723768 B2 JP 5723768B2 JP 2011511892 A JP2011511892 A JP 2011511892A JP 2011511892 A JP2011511892 A JP 2011511892A JP 5723768 B2 JP5723768 B2 JP 5723768B2
Authority
JP
Japan
Prior art keywords
gene
strain
genetically modified
pora
inactivation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011511892A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011521976A5 (https=
JP2011521976A (ja
Inventor
ウェンデル デイビッド ゾリンジャー，
ウェンデル デイビッド ゾリンジャー，
ミハイル ドネッツ，
ミハイル ドネッツ，
デボラ シュミエル，
デボラ シュミエル，
ボリス イオニン，
ボリス イオニン，
ライアン マルケス，
ライアン マルケス，
エリザベス エレン モラン，
エリザベス エレン モラン，
Original Assignee
ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー オブ ジ アーミー， オン ビハーフ オブ ウォルター リード アーミー インスティチュート オブ リサーチ
ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー オブ ジ アーミー， オン ビハーフ オブ ウォルター リード アーミー インスティチュート オブ リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー オブ ジ アーミー， オン ビハーフ オブ ウォルター リード アーミー インスティチュート オブ リサーチ, ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー オブ ジ アーミー， オン ビハーフ オブ ウォルター リード アーミー インスティチュート オブ リサーチ filed Critical ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー オブ ジ アーミー， オン ビハーフ オブ ウォルター リード アーミー インスティチュート オブ リサーチ
Publication of JP2011521976A publication Critical patent/JP2011521976A/ja
Publication of JP2011521976A5 publication Critical patent/JP2011521976A5/ja
Application granted granted Critical
Publication of JP5723768B2 publication Critical patent/JP5723768B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2011511892A 2008-05-30 2009-06-01 髄膜炎菌性多価未変性外膜小胞ワクチン、その作製方法およびその使用 Expired - Fee Related JP5723768B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5746208P 2008-05-30 2008-05-30
US61/057,462 2008-05-30
PCT/US2009/045818 WO2009158142A1 (en) 2008-05-30 2009-06-01 Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014250805A Division JP2015061870A (ja) 2008-05-30 2014-12-11 髄膜炎菌性多価未変性外膜小胞ワクチン、その作製方法およびその使用

Publications (3)

Publication Number Publication Date
JP2011521976A JP2011521976A (ja) 2011-07-28
JP2011521976A5 JP2011521976A5 (https=) 2012-07-12
JP5723768B2 true JP5723768B2 (ja) 2015-05-27

Family

ID=41444870

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011511892A Expired - Fee Related JP5723768B2 (ja) 2008-05-30 2009-06-01 髄膜炎菌性多価未変性外膜小胞ワクチン、その作製方法およびその使用
JP2014250805A Withdrawn JP2015061870A (ja) 2008-05-30 2014-12-11 髄膜炎菌性多価未変性外膜小胞ワクチン、その作製方法およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014250805A Withdrawn JP2015061870A (ja) 2008-05-30 2014-12-11 髄膜炎菌性多価未変性外膜小胞ワクチン、その作製方法およびその使用

Country Status (19)

Country Link
US (2) US9387239B2 (https=)
EP (1) EP2296699A4 (https=)
JP (2) JP5723768B2 (https=)
KR (1) KR20110053314A (https=)
CN (1) CN102105166A (https=)
AU (1) AU2009262893B2 (https=)
BR (1) BRPI0913268A2 (https=)
CA (1) CA2726465A1 (https=)
CO (1) CO6341569A2 (https=)
CR (1) CR11812A (https=)
DO (1) DOP2010000364A (https=)
EC (1) ECSP10010723A (https=)
IL (1) IL209660A0 (https=)
MX (1) MX2010012999A (https=)
NZ (1) NZ589812A (https=)
RU (1) RU2477145C2 (https=)
UA (1) UA99659C2 (https=)
WO (1) WO2009158142A1 (https=)
ZA (1) ZA201008548B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2270173B1 (en) 1999-05-19 2016-01-06 GlaxoSmithKline Biologicals SA Combination neisserial compositions
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
EP2544714A1 (en) * 2010-03-10 2013-01-16 GlaxoSmithKline Biologicals S.A. Vaccine composition
KR101594228B1 (ko) * 2010-08-23 2016-02-15 와이어쓰 엘엘씨 네이세리아 메닌기티디스 ｒＬＰ２０８６ 항원의 안정한 제제
BR112013005626B1 (pt) * 2010-09-10 2022-07-26 Glaxosmithkline Biologicals Sa Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição
GB201015132D0 (en) * 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
CA2846290A1 (en) * 2011-08-31 2013-03-07 Children's Hospital & Research Center Oakland Engineered sequences to facilitate expression of antigens in neisseria and methods of use
JP5957541B2 (ja) * 2012-02-02 2016-07-27 ノバルティス アーゲー 髄膜炎菌における増加したタンパク質発現のためのプロモータ
JP2015517089A (ja) 2012-03-08 2015-06-18 ノバルティス アーゲー タンパク質ベースの髄膜炎菌ワクチンのためのインビトロ有効性アッセイ
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MX359256B (es) 2012-03-09 2018-09-19 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
KR101452830B1 (ko) * 2012-04-06 2014-10-21 아이진 주식회사 두 가지 항암물질을 동시에 제공하는 대장균 균주
US9764027B2 (en) 2012-09-18 2017-09-19 Glaxosmithkline Biologicals Sa Outer membrane vesicles
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
BR112018015237A2 (pt) * 2016-01-28 2018-12-26 De Staat Der Nederlanden Vert Door De Mini Van Vws Miniie Van Volksgezondheid Welzijn En Sport lps de neisseria hexa-acilado modificado
EP3263695A1 (en) 2016-06-29 2018-01-03 GlaxoSmithKline Biologicals SA Immunogenic compositions
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
JP7165468B2 (ja) * 2016-11-25 2022-11-04 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ｎＯＭＶ－抗原コンジュゲート及びその使用
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN107961369B (zh) * 2017-03-22 2020-08-11 武汉博沃生物科技有限公司 多价脑膜炎球菌缀合疫苗及其制备方法
CN114080232A (zh) 2019-03-21 2022-02-22 科迪亚克生物科学公司 用于疫苗递送的细胞外囊泡
EP4034157A1 (en) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN113151354B (zh) * 2021-03-22 2022-03-08 中国农业科学院兰州兽医研究所 一种用于条件性敲除目的基因的载体及条件性敲除目的基因的方法
IT202400003229A1 (it) 2024-02-15 2025-08-15 Cioccio Vito Di Procedimento per la purificazione di omv da batteri gram-negativi, e relativi usi
CN119020251A (zh) * 2024-08-26 2024-11-26 南昌大学 一株脂多糖修饰b群脑膜炎球菌与其外膜囊泡制备及应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US4727136A (en) 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
JP3436756B2 (ja) 1988-12-19 2003-08-18 アメリカン・サイアナミド・カンパニー 髄膜炎菌のクラスｉの外膜タンパク質のワクチン
US7118757B1 (en) * 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
DE4023721A1 (de) 1990-07-26 1992-01-30 Boehringer Mannheim Gmbh Verfahren zur herstellung von vakzinen und ihre verwendung
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
NL9201716A (nl) 1992-10-02 1994-05-02 Nederlanden Staat Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat.
US7112332B1 (en) 1992-10-08 2006-09-26 The United States Of America As Represented By The Secretary Of The Army Oral or intranasal vaccines using hydrophobic complexes having proteosomes and lipopolysaccharides
DK0624376T3 (da) 1993-05-13 2000-07-24 American Cyanamid Co Fremstilling og anvendelse af LOS-udtømte ydre membranproteiner af gram-negative cocci
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
IL123720A (en) 1995-09-18 2002-02-10 Us Army Medical Res Material C Methods for the creation of immune subunits of proteasomes that are multivolent and non-covalently linked
US6558677B2 (en) * 1996-10-15 2003-05-06 Wendell D. Zollinger Vaccine against gram negative bacteria
GB9726398D0 (en) 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
GB9808866D0 (en) 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
US20030215469A1 (en) 1998-11-02 2003-11-20 Microbiological Research Authority Multicomponent meningococcal vaccine
DE60038099T2 (de) 1999-02-22 2009-02-19 Health Protection Agency, Salisbury Neisseria impfstoffzusammensetzungen und methoden
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
PT2289545T (pt) * 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
HU227893B1 (en) 2000-06-29 2012-05-29 Glaxosmithkline Biolog Sa Vaccine compositions
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0024200D0 (en) 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
GB0103169D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
CA2439111A1 (en) 2001-04-05 2002-10-17 Chiron Corporation Mucosal boosting following parenteral priming
GB0130123D0 (en) 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
EP1374892A1 (en) 2002-06-28 2004-01-02 Braun, Jan Matthias, Dr. Medicament for the treatment of diseases due to infection by Neisseria Meningitidis
EP1524991A1 (en) 2002-08-02 2005-04-27 GlaxoSmithKline Biologicals S.A. Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria
CU23377A1 (es) 2003-11-04 2009-05-28 Ct De Ingenieria Genetica Y Biotecnologia Metodo para la incorporacion de antigenos en vesiculas de membrana externa de bacterias y formulaciones resultantes
EP1706481A2 (en) 2003-12-23 2006-10-04 GlaxoSmithKline Biologicals S.A. Vaccine
JP5174457B2 (ja) * 2004-05-11 2013-04-03 デ スタート デール ネーダーランデン， フェルテヘンウォールディヒィト ドール デ ミニステール ファン フォルクスヘーゾンドハイド， フェルザイン アン スポルト アジュバントとしての髄膜炎菌ｌｇｔＢＬＯＳ
US7537766B2 (en) * 2004-08-30 2009-05-26 Wyeth Neisseria meningitidis inner core lipo-oligosaccharide epitopes, multivalent conjugates thereof and immunogenic compositions thereof
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
ES2616294T3 (es) * 2005-01-27 2017-06-12 Children's Hospital & Research Center At Oakland Vacunas de vesículas basadas en GNA1870 para protección de amplio espectro contra enfermedades provocadas por Neisseria meningitidis
DE602007003596D1 (de) * 2006-06-12 2010-01-14 Glaxosmithkline Biolog Sa Impfstoff

Also Published As

Publication number Publication date
ZA201008548B (en) 2012-06-27
KR20110053314A (ko) 2011-05-20
IL209660A0 (en) 2011-02-28
AU2009262893A9 (en) 2015-05-21
WO2009158142A1 (en) 2009-12-30
US20170100471A1 (en) 2017-04-13
RU2010153658A (ru) 2012-08-10
NZ589812A (en) 2012-08-31
MX2010012999A (es) 2012-03-07
AU2009262893B2 (en) 2015-05-21
CO6341569A2 (es) 2011-11-21
AU2009262893A1 (en) 2009-12-30
EP2296699A4 (en) 2013-11-13
CN102105166A (zh) 2011-06-22
CA2726465A1 (en) 2009-12-30
BRPI0913268A2 (pt) 2016-03-15
US20110182942A1 (en) 2011-07-28
UA99659C2 (uk) 2012-09-10
ECSP10010723A (es) 2011-05-31
CR11812A (es) 2011-07-06
EP2296699A1 (en) 2011-03-23
JP2011521976A (ja) 2011-07-28
JP2015061870A (ja) 2015-04-02
US9387239B2 (en) 2016-07-12
RU2477145C2 (ru) 2013-03-10
DOP2010000364A (es) 2011-07-15

Similar Documents

Publication Publication Date Title
JP5723768B2 (ja) 髄膜炎菌性多価未変性外膜小胞ワクチン、その作製方法およびその使用
US20090117147A1 (en) Vaccines comprising outer membrane vesicles from gram negative bacteria
CN1377415B (zh) 疫苗组合物
JP6077983B2 (ja) 外膜タンパク質を有する免疫原性細菌小胞
AU2003270970B2 (en) Vaccine composition
HK1105576A (en) Genetically engineered bleb vaccine
HK1105575A (en) Meningococcal vaccine composition
HK1108004A (en) Genetically engineered bleb vaccine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120525

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131225

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140131

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140303

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140811

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141211

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150305

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150330

R150 Certificate of patent or registration of utility model

Ref document number: 5723768

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees